About PreComb

PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring precision medicine benefits to all cancer patients. PreComb is pioneering breakthrough technologies to directly test the drug response of individual cancer patients, based on patient-derived 3D microtumors. For the first time, a fully automated point-of-care solution for determining drug sensitivity or resistance directly in the clinic is being developed. This offers the unique ability to routinely test entire portfolios of cancer drugs and drug combinations in large-scale, making the technology a universal tool from drug discovery to guiding therapies.

Press releases

Press
26. April 2021

PreComb Therapeutics AG secures CHF 2.2 Mio seed financing to advance personalized medicine for cancer patients

PreComb develops the next generation point-of-care technology for patient-specific profiling of cancer therapies PreComb Therapeutics today announced the successful completion of the seed financing round led by Kinled Austria, the High-Tech Gründerfonds and FiveT capital, in addition to participations from other investors. Patrick Aisher, managing partner at Kinled Austria, joined the company’s board of directors. The seed funding will help advance the proprietary 3D3 Technol
 

Info & Contact

Address

PreComb Therapeutics AG
Garstligweg 8
CH-8634 Hombrechtikon
Switzerland

In portfolio

01. Dec 2014

Sector

 

Dr. Anke Caßing

Principal / Authorized Signatory